We are always evolving in an ever-changing industry.

Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated, a PrECOG early-phase trial shows

Trial PrE0405 met its primary endpoint. Venetoclax combined with bendamustine+rituximab as the first therapy for MCL in patients over age 60 led to a complete response rate of 85%. The American Society of Hematology 2023 annual meeting featured the data. The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate […]